Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody^*

References

• Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5(10):e362.
   PubMed Web of Science ®Google Scholar
• Garcia Munoz R, Izquierdo-Gil A, Munoz A, et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93(11):1879–1887.
   PubMed Web of Science ®Google Scholar
• Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomized phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006;132:105–112.
   PubMed Web of Science ®Google Scholar
• Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378–4384.
   PubMed Web of Science ®Google Scholar
• Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013;92(5):653–660.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) show superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advance chronic lymphocytic leukemia: final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts). 2014;124:19.
   Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle‐cell lymphomas: a multicentre, randomised, open‐label, noninferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Ribakowski E, Mizrahi N, et al. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma. 2016;57(1):63–69.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Aktan M, Hiddemann W, et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018;103(4):698–706.
   PubMed Web of Science ®Google Scholar
• Abkur TM, Saeed M, Ahmed SZ, et al. Pneumocystis jiroveci prophylaxis in patients undergoing bendamustine treatment: the need for a standardized protocol. Clin Case Rep. 2015;3(4):255–259.
   PubMed Web of Science ®Google Scholar
• Carter SJ, Bernstein SH, Friedberg JW, et al. Pneumocystis jiroveci pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011;35(11):e223–4.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Ogasawara R, Miyashita N, et al. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol. 2012;95(5):588–591.
   PubMed Web of Science ®Google Scholar
• Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol. 2012;91(4):643.
   PubMed Web of Science ®Google Scholar
• Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent Non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019;68(2):247–255.
   PubMed Web of Science ®Google Scholar
• CTCAE v4.0, NCI, Bethesda (MD). [cited 2009 Dec 23]. Available from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. [cited 2019 Sep 12]. Available from: https://www.R-project.org/.
   Google Scholar
• Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512–519.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36:2395–2404.
   PubMed Web of Science ®Google Scholar
• Network NCC. B-Cell Lymphomas (Version 4). National Comprehensive Cancer Network; 2018 [cited 2018 Jul 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
   Google Scholar
• Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel – an update. Leuk Lymphoma. 2016;57(4):766–782.
   PubMed Web of Science ®Google Scholar
• Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist. 2013;18(8):954–964.
   PubMed Web of Science ®Google Scholar